ORIC PHARMACEUTICALS

9.8700

25-November-24 15:45:01

15 minutes delayed

Stocks

+0.2800

+2.92%

Today's range

9.6700 - 10.0600

ISIN

N/A

Source

NASDAQ

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

05 Apr 2024 15:30:00 By Nasdaq GlobeNewswire
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

04 Apr 2024 15:30:00 By Nasdaq GlobeNewswire
ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Updates

11 Mar 2024 15:05:00 By Nasdaq GlobeNewswire
ORIC Pharmaceuticals to Present at the Leerink Partners Global Biopharma Conference

06 Mar 2024 15:30:00 By Nasdaq GlobeNewswire
ORIC Pharmaceuticals Announces Multiple Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting

05 Mar 2024 15:30:00 By Nasdaq GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

01 Mar 2024 15:30:00 By Nasdaq GlobeNewswire
ORIC Pharmaceuticals to Participate in the Citi 2024 Virtual Oncology Leadership Summit

14 Feb 2024 15:30:00 By Nasdaq GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

02 Feb 2024 15:30:00 By Nasdaq GlobeNewswire
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

31 Jan 2024 15:30:00 By Nasdaq GlobeNewswire
ORIC Pharmaceuticals Announces $125 Million Private Placement Financing

22 Jan 2024 07:30:00 By Nasdaq GlobeNewswire
ORIC Pharmaceuticals Provides Initial Phase 1b Data for ORIC-944, Operational Highlights for 2023, and Anticipated Upcoming Milestones

08 Jan 2024 07:30:00 By Nasdaq GlobeNewswire
ORIC Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

02 Jan 2024 15:30:00 By Nasdaq GlobeNewswire
Initial Phase 1 Dose Escalation Data for ORIC-533 in Relapsed/Refractory Multiple Myeloma Demonstrates Clinical Activity and Strong Safety Profile Supporting Potential for Combination Development

11 Dec 2023 11:00:00 By Nasdaq GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

01 Dec 2023 15:30:00 By Nasdaq GlobeNewswire
ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

09 Nov 2023 15:30:00 By Nasdaq GlobeNewswire
ORIC Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates

06 Nov 2023 15:10:00 By Nasdaq GlobeNewswire
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

03 Nov 2023 15:30:00 By Nasdaq GlobeNewswire
ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC-533 in Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting

02 Nov 2023 08:00:00 By Nasdaq GlobeNewswire
Initial Phase 1 Dose Escalation Data of ORIC-114 in Patients with EGFR and HER2 Exon 20 Mutations Demonstrates Potential Best-In-Class Profile

21 Oct 2023 06:30:00 By Nasdaq GlobeNewswire
ORIC Pharmaceuticals to Present Initial Phase 1b Clinical Data for ORIC 114 in EGFR/HER2 Exon 20 Mutated NSCLC at the European Society of Medical Oncology (ESMO) Congress 2023

17 Oct 2023 15:30:00 By Nasdaq GlobeNewswire

<<
<
1
2
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.